common.study.topics.clinical

Measuring Metastatic Risk in Breast Cancer

common.study.values.description

Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment

The primary aim of the study is to identify genomic and circulating tumor cell (CTC) markers as biomarkers of response to chemotherapy among patients with invasive breast cancer. The secondary aim of this study is to use genomic and CTC markers to evaluate metastatic risk in breast cancer following primary treatments.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Diagnostic Test - Genomic and CTC Markers

This is a non-interventional study.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment

common.study.values.clinical-trial-id

NCT03709134

participant.views.study.view.id

b4xL1b